Announcements Trials
Browse Landscape

Phase

Phase 1 145Phase 2 118Phase 1/2 97Phase 3 37Phase NA 22Phase EARLY_PHASE1 6Phase 4 5Phase 2/3 5

Status

Active not recruiting 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 9INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 22Breast Neoplasms 20Neoplasm Metastasis 18Colorectal Neoplasms 16Stomach Neoplasms 15Recurrence 15Prostatic Neoplasms 15Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Ovarian Neoplasms 11Head and Neck Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Myasthenia Gravis 9Melanoma 9Leukemia, Myeloid, Acute 9Urinary Bladder Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Lymphoma, Follicular 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5

Interventions

Temozolomide 4vocimagene amiretrorepvec 1Lomustine 1Flucytosine 1Etoposide 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Glioblastoma × Clear all
NCT06105619 2026-01-20

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Beijing Pearl Biotechnology Limited Liability Company

Phase 2/3 Active not recruiting
84 enrolled
CNS

Glioblastoma

NCT07349693 2026-01-20

Cerebraca-02/3

Everfront Biotech Co., Ltd.

Phase 2/3 Not yet recruiting
175 enrolled
CNS

Glioblastoma

NCT04250922 2025-11-20

CLINGLIO

Laminar Pharmaceuticals

Phase 2/3 Active not recruiting
144 enrolled
CNS

Glioblastoma

NCT03008148 2021-05-11

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Johnpro Biotech, Inc.

Phase 2/3 Unknown
288 enrolled
CNS

Glioblastoma

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated
403 enrolled
CNS

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡